![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Hordinsky, Maria K., MD National Alopecia Areata Foundation |
---|---|
Information provided by: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT00176943 |
It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle.
Condition | Intervention | Phase |
---|---|---|
Alopecia Areata |
Drug: Aldara Cream 5% |
Phase IV |
Study Type: | Interventional |
Study Design: | Educational/Counseling/Training, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry |
Estimated Enrollment: | 20 |
Study Start Date: | October 2000 |
Estimated Study Completion Date: | August 2002 |
We will examine how the application of Aldara Cream 5% daily for 6 months will affect the hair follicle and the inflammation present in the skin of patients with alopecia areata. In the study we will obtain additional scalp biopsies to examine how the drug affects the quality and state of activity of the immune cells in the biopsy specimens. This type of information will provide data about the behavior of these inflammatory cells in mediating the hair loss associated with alopecia areata and how this behavior may be effected by Aldara Cream 5% treatment. Such information may be valuable to the successful management of alopecia areata.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 |
Principal Investigator: | Maria Hordinsky, MD | University of Minnesota |
Principal Investigator: | Marna Ericson, PhD | University of Minnesota |
Study ID Numbers: | 0009M64941 |
Study First Received: | September 12, 2005 |
Last Updated: | November 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00176943 History of Changes |
Health Authority: | United States: Institutional Review Board |
Pathological Conditions, Anatomical Alopecia Areata Hypotrichosis Immunologic Factors Skin Diseases |
Alopecia Interferons Adjuvants, Immunologic Imiquimod |
Hair Diseases Pathological Conditions, Anatomical Interferon Inducers Hypotrichosis Skin Diseases Immunologic Factors Antineoplastic Agents |
Physiological Effects of Drugs Adjuvants, Immunologic Imiquimod Pharmacologic Actions Alopecia Areata Alopecia Therapeutic Uses |